secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2021-12-17T23:59:59+00:00
Accession:  0001193125-21-359961
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AlloVir CMO Agustin Melian to depart at year-end; Richard Riese to lead clinical programs
--------------------------------------------------------------------------------

- CMO Agustin Melian, MD, leaves AlloVir at end of 2021 after two and a half years.
- Melian will serve in an advisory role for transition; CEO thanked him for advancing posoleucel into Phase 3.
- Richard Riese, MD, PhD, SVP Clinical Research, will oversee clinical development including Phase 3 posoleucel studies.
- Company's pipeline of virus-specific T cells continues; no change to clinical strategy disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/0001193125-21-359961-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312521359961/d256659d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-359961

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer